CORE--VIROLOGY

病毒学核心将作为Well的集中来源 表征了HIV-1、HIV-2和SIV毒株的库存。此外 到标准的、原型的实验室菌株，样本银行核心 将从特征良好的临床材料中提供分离株，并且 分子生物学核心将提供获得的基因定义的分离株 通过DNA导入感染性分子克隆。股票将会是 在适当的宿主细胞中产生(原代CD4+T细胞、单核细胞- 衍生的巨噬细胞或细胞系)，等份，并在-80℃或 在液氮中。核心将标准化的描述 这些病毒(这应该会提高参与的质量 CFAR研究单位)，从而消除了大量重复工作。 将进行三个方面的表征：(1)病毒滴定 相关宿主细胞类型的菌株；(2)病毒菌株的表型 (细胞嗜性、合胞体诱导(SI)与非SI、细胞病变与 非细胞病变、复制动力学、药物敏感性等)； (3)研究调查性干预的效果(基因 治疗、抗病毒化合物、抗体中和等)。在……里面 此外，核心将提供分离的CD4+细胞和巨噬细胞，这 从技术上讲很难准备好。这些核心的可用性 病毒式库存和服务应该扩展 使用其服务的调查人员。

The Virology Core will serve as a centralized source for well characterized stocks of strains of HIV-1, HIV-2, and SIV. In addition to the standard, prototypic laboratory strains, the Specimen Banking Core will provide isolates from well-characterized clinical material and the Molecular Biology Core will provide genetically defined isolates obtained by DNA transfections of infectious molecular clones. Stocks will be produced in the appropriate host cell (primary CD4+T cells, monocyte- derived macrophages, or cell lines), aliquotted, and archive at -80 C or in liquid nitrogen. The Core will standardize the characterization of theses viruses (which should enhance the quality of the participating CFAR research units) and thereby eliminate much duplication of effort. Three areas of characterization will be performed: (1) tittering of viral strains in the relevant host cells type; (2) phenotyping of viral strains (cell tropism, syncytium-inducing (SI) versus non-SI, cytopathic versus non-cytopathic, replication kinetics, drug susceptibilities, etc.); an (3) studying the effects of investigational interventions (gene therapies, antiviral compounds, antibody neutralization, etc.). In addition, the Core will supply isolated CD4+ cells and macrophages, which are technically difficult to prepare. The availability of these Core viral stocks and services should extend the experimental capabilities of the investigators who use its services.